- Home
- ICCM vs CCM Comparison
ICCM vs CCM Comparison
Compare ICCM & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | CCM |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | | Medical/Nursing Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 19.0M |
| IPO Year | 2013 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ICCM | CCM |
|---|---|---|
| Price | $2.83 | $5.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 72.0K | 62.0K |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $139.51 | N/A |
| Revenue Next Year | $75.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $3.18 |
| 52 Week High | $9.54 | $6.98 |
Technical Indicators
Market Signals| Indicator | ICCM | CCM |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 52.60 |
| Support Level | $2.71 | $4.41 |
| Resistance Level | $3.59 | $5.38 |
| Average True Range (ATR) | 0.32 | 0.55 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 20.78 | 44.66 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.